Market Research Report: Cytiva

Company Overview

Name: Cytiva

Mission of the Company: _"At Cytiva, we envision a world in which access to life-changing therapies transforms human health. Our wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery."_

Founding and Founders: No information is available

Key People: Pierre-Alain Ruffieux, Chief Operating Officer

Headquarters: No information is available

Number of Employees: 15,000 associates

Revenue of the Company: No information is available

Primary Recognition:

• Part of Danaher, a global science and technology leader.

• Recognized for antibody purification.

Products

1. Bioprocessing Solutions

• Description: End-to-end solutions supporting the journey from discovery to delivery.

• Key Features:

• Support for process development, intensification, and scaling.

• Suitable for monoclonal antibodies, antibody variants, viral vectors, vaccines, recombinant proteins, cell and gene therapies, mRNA, and oligonucleotides.

2. Advanced Therapies

• Description: Solutions for mRNA-LNP production, cell therapy production, gene therapy production, LNP therapeutics, therapeutic oligos.

• Key Features:

• Comprehensive support from research to manufacturing.

• Tools to accelerate the production and commercialization process.

3. Diagnostics

• Description: Tools to accelerate the development and commercialization of diagnostic assays and kits.

• Key Features:

• Support for lab-based molecular and immuno diagnostics, and point-of-care (POC) diagnostics.

• Customized services for reagent characterization, assay development, and lyophilization.

4. Genomics

• Description: Solutions for disease identification and the development of targeted therapies.

• Key Features:

• Optimization of DNA and RNA extraction.

• Technologies for amplification, enrichment, sequencing, and single-cell sequencing.

5. Laboratory Filtration

• Description: Filtration solutions for research labs, QC, and field applications.

• Key Features:

• Devices for analytical testing, cannabis sample prep, environmental monitoring, industrial applications, microbiology, and food and beverage testing.

6. Medical Filtration

• Description: Filtration and membrane solutions for healthcare professionals, medical device manufacturers, and patients.

• Key Features:

• Anesthesia, intensive care ventilation, and surgical gas handling filtration.

• IV filtration, OEM membrane filtration, and water filtration solutions.

7. Protein Research

• Description: Workflow solutions from isolation and sequencing to sample preparation.

• Key Features:

• Protein purification systems and accessories.

• Support for chromatography and biacore analysis.

Recent Developments

1. New Leadership:

• Pierre-Alain Ruffieux joined as Chief Operating Officer.

2. Innovations and Releases:

• Cytiva’s latest FlexFactory platform for oligonucleotides introduced at Ribobay Pharma.

• Supor Prime sterilizing grade filters launched for improved filtration of high concentration biologics.

3. Support and Partnerships:

• Collaboration with AGC Biologics to provide FlexFactory platforms for a new biomanufacturing facility in Japan.

• Continued support for n-Lorem Foundation.

4. Sustainability Efforts:

• Published the Global Biopharma Sustainability Review examining biopharma sustainability efforts.

• Committed to Net Zero GHG emission reduction targets.

5. Product Developments:

• New cell lines to meet the demands of viral vector manufacturing.

• Innovative tools for next generation cell therapy manufacturing.

6. Customer Support:

• Remote troubleshooting tools like OptiRun™ View aiding in customer support.

Summary

Cytiva is a global life sciences leader with a mission to transform human health through therapeutic advancements. They support biopharma across various stages of therapeutic development with innovative products, detailed process support, and a strong emphasis on sustainability. Recently, they have enhanced their filament technology, entered into strategic partnerships, and launched new products to sustain their market position in the rapidly evolving biopharma industry.